Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30 2024 - 9:00AM
Kamari Pharma, a privately-held clinical stage biotechnology
company developing first and best-in-class treatments for rare and
severe genetic skin diseases, today announced the appointment of
John Doux, MD, MBA, to the company’s Board of Directors. Dr. Doux
is a board-certified dermatologist and analyst at Palo Alto
Investors, a physician-led healthcare focused investment
firm.
“We are pleased to welcome John to our board of
directors at this exciting time for Kamari. John is a highly
accomplished life science investor and dermatologist, with
extensive industry and market insight, as well as experience in
drug development and patient care,” said Dr. David Aviezer,
Executive Chairman of Kamari Pharma. “John’s guidance will be
instrumental to Kamari as we embark on Phase 2 development of
KM-001, a topical TRPV3 inhibitor for palmoplantar keratodermas,
and Phase 1 development of KM-023, an oral TRPV3 inhibitor for
Olmstead syndrome, palmoplantar keratodermas and Ichthyosis.”
Dr. Doux has been an analyst at Palo Alto
Investors since 2004. He currently serves as a board director of
Lutris Pharma, and previously served as board chair of ValenzaBio
(acquired by ACELYRIN), board director of Ceptaris Therapeutics
(acquired by Actelion Pharmaceuticals) and Palvella Therapeutics.
Dr. Doux is also a board-certified dermatologist, fellow of the
American Academy of Dermatology and a co-founder and prior board
member of the Dermatology Summit and Dermatology Innovation Forum.
He earned his bachelor and medical degrees from Stanford
University, where he was a Howard Hughes Medical Institute Fellow
in the laboratory of Dr. David Woodley. Dr. Doux completed his
training at Brigham and Women’s Hospital and Stanford Medical
Center and earned an MBA at the Wharton School of Business, where
he was a Palmer Scholar.
“Kamari’s approach to inhibiting TRPV3
represents a unique opportunity to develop first-in-class
disease-modifying treatments for a number of rare and serious
genetic skin diseases,” said Dr. John Doux. “I am pleased to
join Kamari’s Board and look forward to leveraging my strategic
perspective on translational science, clinical development and
capital markets to help the Company deliver on its mission to bring
innovative therapies to patients.”
About Kamari Pharma
Kamari Pharma is a privately-held clinical stage
biotechnology company developing first and best in class treatments
for rare and severe genetic skin diseases. Kamari’s lead molecules,
KM-001 (topical) and KM-023 (oral) are novel, highly specific and
selective TRPV3 inhibitors that are initially being developed to
treat palmoplantar keratodermas, Olmstead syndrome and Ichthyosis.
Kamari’s management team is comprised of industry leaders highly
experienced in drug discovery, dermatological pharmaceutical
development and rare disease drug development.
Contact Information
Investors and MediaMarcy NanusManaging PartnerTrilon Advisors,
LLCmnanus@trilonadvisors.com